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Purpose: To evaluate the clinical outcomes and incremental health care costs of ischemic stroke 
in a US managed care population.
Patients and methods: A retrospective cohort analysis was done on patients (aged 18+ years) 
hospitalized with noncardioembolic ischemic stroke from January 1, 2002, through   December 
31, 2003, identified from commercial health plan administrative claims. New or recurrent stroke 
was based on history in the previous 12 months, with index date defined as first date of   indication 
of stroke. A control group without stroke or transient ischemic attack (TIA) was matched (1:3) 
on age, sex, and geographic region, with an index date defined as the first   medical claim during 
the patient identification period. Patients with atrial fibrillation or mitral value abnormalities 
were excluded. Ischemic stroke and control cohorts were compared on 4-year clinical outcomes 
and 1-year costs.
Results: Of 2180 ischemic stroke patients, 1808 (82.9%) had new stroke and 372 (17.1%) 
had a recurrent stroke. Stroke patients had higher unadjusted rates of additional stroke, TIA, 
and fatal outcomes compared with the 6540 matched controls. Recurrent stroke patients had 
higher rates of adverse clinical outcomes compared with new stroke patients; costs attributed to 
recurrent stroke were also higher. Stroke patients were 2.4 times more likely to be hospitalized 
in follow-up compared with controls (hazard ratio [HR] 2.4, 95% confidence interval [CI]: 2.2, 
2.6). Occurrence of stroke following discharge was 21 times more likely among patients with 
index stroke compared with controls (HR 21.0, 95% CI: 16.1, 27.3). Stroke was also predictive 
of death (HR 1.8, 95% CI: 1.3, 2.5). Controlling for covariates, stroke patients had significantly 
higher costs compared with control patients in the year following the index event.
Conclusion: Noncardioembolic ischemic stroke patients had significantly poorer outcomes 
and higher costs compared with controls. Recurrent stroke appears to contribute substantially 
to these higher rates of adverse outcomes and costs.
Keywords: burden of illness, stroke/cerebrovascular accident, cardiovascular disease, claims 
analysis, costs of care, health care outcomes
Background
Stroke is a major cause of serious, long-term disability, mortality, and institutionalization, 
and it accounts for substantial use of health care resources.1–4 When considered 
  separately from other cardiovascular diseases, stroke ranks third among all causes of 
death, following diseases of the heart and cancer.5 Among survivors, ∼15%–30% are 
permanently disabled and 20% require institutional care 3 months after onset.6 As a 
result, stroke imposes a significant economic impact, with stroke-related costs   making 
up as much as 3%–4% of the annual national health care budget.1,2 For 2009, the 
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The burden of stroke is often measured in terms of the 
incidence rates of first stroke, but the prevalence of total 
stroke (ie, first stroke plus recurrent stroke) more accurately 
reflects the true burden.7,8 Nearly 30% of all strokes are 
recurrent events, and the risk is highest in the period 
immediately following a stroke.9 It has been estimated that 
within 1 year after the first stroke, the risk of recurrence is 
15 times the risk of stroke in the general population.10 Of 
those who have had first stroke, the percentages of men and 
women aged 40–69 years with a recurrent stroke in 5 years are 
13% and 22%, respectively. At the age of 70 years, the risk of 
recurrent stroke is 23% in men and 28% in women.6 This sug-
gests that prevention of stroke recurrence must be a primary 
goal of acute and long-term management of stroke.11
Recurrent strokes tend to inflict greater neurological 
impairment and more severe disability than the first stroke, 
and patients with recurrent strokes tend to have poorer health 
and economic outcomes than those with first strokes.7,9,12 
In a Medicare claims-based analysis conducted by Samsa 
et al7 survival from first stroke (56.7% at 24 months) was 
consistently better than that for recurrent stroke (48.3% at 
24 months). In addition, patients with recurrent stroke had 
significantly higher health care costs following their stroke 
compared with patients with first stroke.
Although the literature provides some evidence of the 
incremental costs and adverse clinical outcomes associated 
with recurrent stroke in a Medicare patient population, the 
extent to which the findings apply to a younger, commercially 
insured population has not been fully explored. This claims-
based retrospective analysis was designed to evaluate clinical 
outcomes and costs associated with noncardioembolic 
ischemic stroke compared with the general managed care 
population. Furthermore, the study explored the relative 
impact of new versus recurrent stroke.
Methods
Data source
This was a retrospective administrative claims data study 
using eligibility, medical, and pharmacy claims data from a 
large US managed care plan affiliated with i3 Innovus. The 
individuals covered by this health plan were geographically 
diverse across the United States, with enrollees in all four US 
Census regions. The plan provides fully insured coverage for 
physician, hospital, and prescription drug services. The data 
are linked longitudinally using an encrypted patient ID.
The database contained enrollment and claims data 
for 10.7 million commercial health plan enrollees during 
the identification period of January 1, 2002, through 
December 31, 2003. Claims data for the assessment of patient 
characteristics and outcomes among those identified and 
retained for analysis ranged from January 1, 2001, through 
December 31, 2005.
sample selection
Patients were selected for the ischemic stroke cohort if they 
were aged at least 18 years, were hospitalized for ischemic 
stroke during the 2-year identification period, and had no diag-
nostic evidence during the identification period of atrial fibril-
lation (AF) or mitral valve abnormalities (ICD-9-CM codes 
427.31, 746.5, 396.0, 396.1, 394.2, 394.0, 424.0, 391.1, 392.0, 
398.90, 398.99). Inpatient hospital claims were examined for 
evidence of stroke based on a qualifying diagnosis code (ICD-
9-CM codes 362.31–362.34, 430.xx–432.xx, 433.x1, 434.x1, 
436.xx, and 438.xx) in the primary diagnosis position on a 
claim.7 Patients were included in the stroke cohort if they had 
a diagnosis for ischemic stroke; patients without ischemic 
stroke either during the index hospitalization or during the 
pre-index period were excluded. Patients were categorized 
as new ischemic stroke patients if the hospitalization was 
for ischemic stroke and there was no evidence of any prior 
stroke during the pre-index period. Patients were categorized 
as recurrent stroke patients if there was evidence of ischemic 
stroke in the 12-month period prior to the index stroke hos-
pitalization (pre-index period). Qualifying stroke patients 
were required to be continuously enrolled in the health plan 
with medical and pharmacy benefits for 12 months prior to 
the admission date for the index hospitalization. Variable 
follow-up observation was permitted until the earliest of 
death (identified from discharge hospital claims), 48 months 
of observation, or December 31, 2005.
A general population of adult control subjects with at least 
1 month of enrollment during the identification period was 
randomly selected from the database. An index date was set 
based on the first service date on a medical claim during the 
patient identification period. Potential controls were retained 
if they met the 12-month pre-index continuous enrollment 
requirement and had no evidence of stroke, transient ischemic 
attack (TIA), AF, or mitral valve abnormalities during the pre-
index period. The non stroke control population was matched 
3:1 to stroke patients on age, sex, and geographic region.
Outcome variables
Outcomes were measured in the claims data during the 
variable follow-up period from the day following discharge 
among stroke patients or control patients with an index 
hospitalization, or from the index date among control patients Vascular Health and Risk Management 2010:6 submit your manuscript | www.dovepress.com
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not hospitalized on index. Two types of outcomes were 
analyzed for this study. First, clinical outcomes including 
hospitalization, stroke, TIA, and death were assessed in 
the variable follow-up period (up to 4 years). Second, 
index hospitalization, medical, pharmacy, and total costs of 
health care services were examined in the year following 
stroke. Costs were calculated as the patient and health plan 
paid amounts for services delivered (regardless of direct 
relationship to the condition of ‘stroke’) in the 12 months 
following discharge or index date among those with no 
hospitalization on index. Costs were adjusted to 2005 values 
based on the medical component of the Chained Consumer 
Price Index13 and were converted to a per-patient-per-year 
measure to account for the variable observation in the 
12 months following the index date.
independent variables
Stroke and control cohorts were the primary variable of 
interest. In addition, age, gender, and US Census region in 
which the patient lived were derived from the enrollment data. 
Claims from the pre-index period were assessed for evidence 
of comorbid illnesses, specifically hypertension, diabetes, 
TIA, chronic obstructive pulmonary disease (COPD), con-
gestive heart failure (CHF), and myocardial infarction (MI).
statistical methods
Bivariate comparisons between the stroke cohort and the 
control cohort were conducted for all study variables. For 
comparison of mean, t-tests were used for continuous 
measures and χ2 tests of differences in proportions were 
used for dichotomous or ordinal variables. All results are 
also shown for new and recurrent stroke patients, although 
no testing was performed. Costs, mortality, additional 
stroke, and additional hospitalization were further analyzed 
using appropriate multivariable statistical methods. Time 
to hospitalization, time to stroke, and time to death were 
analyzed using time-to-event analysis techniques to allow 
for differing follow-up times. Specifically, Cox proportional 
hazard models were estimated and Kaplan–Meier curves were 
presented for each of these outcomes. Wilcoxon and Log-rank 
tests were performed for the Kaplan–Meier analyses to test 
for differences across the cohorts. Tests of the proportional-
ity assumption were performed for the Cox proportional 
hazards models to determine whether the hazards remained 
constant over time.
Medical or pharmaceutical costs are difficult to model 
because of the skewed nature of the distribution of costs 
(ie, many subjects have minimal or no costs during the 
study period whereas a few subjects have extremely high 
costs). Therefore, to compensate for the skewed distribution, 
we estimated costs using a generalized linear model with 
gamma distribution and log link. For the disease cohort 
variable, the coefficients from the generalized linear 
modeling specification represent the ratio of expected costs 
in the disease cohort versus the control cohort. This method 
avoids potential difficulties introduced by transformation 
(eg, calculating the log of the costs) and retransformation of 
the dependent variable.14 Independent variables included the 
presence of stroke during the baseline period, age, gender, 
geographic region, and comorbid illness. Interaction terms 
between age and gender were tested and included in the 
models where statistically significant.
SAS software (v. 8.2; SAS Institute Inc., Cary, NC) was 
used for creation of the analytic dataset and descriptive 
analyses, and STATA software (v. 9; StataCorp LP, College 
Station, TX) was used for multivariate analyses.
Results
Patient characteristics
Of the 10.7 million health plan enrollees in the research 
database during the identification period from January 1, 
2002, to December 31, 2003, 39,446 patients were identified 
with ischemic stroke, hemorrhagic stroke, unknown stroke, or 
TIA. From this group, patients were excluded due to mitral 
valve abnormality, AF, age, application of the 12-month pre-
index continuous enrollment requirement, and finally down 
to patients with ischemic stroke on the index date. These 
patients were then matched 3:1 to controls. The final sample 
retained 2180 ischemic stroke patients, including 1808 new 
stroke patients and 372 recurrent stroke patients, and 6540 
control patients.
Table 1 shows the demographic and baseline charac-
teristics of the study cohorts. Mean age of both the stroke 
and control cohorts was 59 (SD 13) years. More than half 
of all study patients were 55 years of age or older. Men 
represented 58.49% of the stroke and control cohorts. 
Within the stroke cohort, new stroke patients were more 
likely to be male (59.07%) compared with the recurrent 
stroke patients (55.65%). The recurrent stroke subgroup 
had a larger percentage of patients 65 years of age or older. 
The distribution across the four geographic regions was 
similar between the stroke and control cohorts, and across 
new and recurrent stroke patients; reflective of the distri-
bution of the research database population, the majority 
of the patients were either from the Midwest (41.4%) or 
South (40.4%).Vascular Health and Risk Management 2010:6 submit your manuscript | www.dovepress.com
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Length of follow-up varied widely between the cohorts. 
Controls had the longest average follow-up available with 
900 (SD 446) days compared with 571 (SD 433) days for 
the stroke cohort (P , 0.001). Within the stroke cohort, new 
stroke patients averaged 587 (SD 432) days of follow-up, 
and recurrent stroke patients averaged 489 (SD 429) days 
of follow-up.
The stroke cohort was significantly more likely to have 
pre-existing comorbid disease compared with the control 
cohort. Hypertension was common, present in 54.1% of 
stroke patients, compared with 28.10% of control patients 
(P , 0.001). Diabetes was also highly prevalent, identified 
in 27.6% of stroke patients compared with 10.0% of controls 
(P , 0.001). All comorbid conditions were more prevalent in 
recurrent stroke patients compared with new stroke patients.
Unadjusted analysis
Stroke patients had a significantly higher rate of incident 
hospitalization during follow-up compared with controls. 
A total of 752 (34.5%) stroke patients were hospitalized 
in follow-up for a rate of 307 incident hospitalizations 
per 1000 patient-years. Comparatively, 21.2% of control 
patients were hospitalized at a rate of 100 per 1000 patient-
years. Patients with recurrent stroke had the highest rate 
of hospitalization (382 incident hospitalizations per 1000 
patient-years) compared with new stroke patients, who 
had 294 incident hospitalizations per 1000 patient-years. 
A total of 340 stroke patients (15.6%) experienced a sub-
sequent stroke following index hospital discharge for an 
incident rate of 115 strokes per 1000 patient-years. This 
was a substantially higher rate compared with the control 
patients (5 strokes per 1000 patient-years). The rate of fatal 
stroke was 6 per 1000 patient-years for all stroke patients 
compared with ,1 for control subjects. Among recurrent 
stroke patients, additional stroke had an incident rate of 
165 per 1000 patient-years, whereas fatal strokes had 
an incident rate of 8 per 1000 patient-years. New stroke 
patients were comparatively less likely to experience 
an additional stroke (107 strokes and 5 fatal strokes per 
1000 patient-years).
The incidence of post-index date TIA was higher among 
stroke patients than that in controls (186 incident TIA 
Table 1 Demographic characteristics
Stroke cohort 
(N = 2180)
New stroke 
(N = 1808)
Recurrent 
stroke (N = 372)
Control cohort 
(N = 6540)
Days of observation, 
mean ± sD
571 ± 433* 587 ± 432 489 ± 429 900 ± 446
Pre-index costs,  
mean ± sD
$8085 ± $17,340* $7014 ± $16,054 $13,293 ± $21,860 $3142 ± $7264
Age, mean ± sD 59 ± 13 59 ± 13 60 ± 13 59 ± 13
Age group, n (%)
  18–24 13 (0.6) 12 (0.7) 1 (0.3) 39 (0.6)
  25–34 51 (2.3) 42 (2.3) 9 (2.4) 153 (2.3)
  35–44 190 (8.7) 159 (8.8) 31 (8.3) 570 (8.7)
  45–54 513 (23.5) 433 (24.0) 80 (21.5) 1539 (23.5)
  55–64 794 (36.4) 665 (36.8) 129 (34.7) 2382 (36.4)
  65+ 619 (28.4) 497 (27.5) 122 (32.8) 1857 (28.4)
sex, n (%)
  Female 905 (41.5) 740 (40.9) 165 (44.35) 2715 (41.5)
  Male 1275 (58.5) 1068 (59.1) 207 (55.65) 3825 (58.5)
Region, n (%)
  Northeast 220 (10.1) 185 (10.2) 35 (9.41) 659 (10.1)
  Midwest 902 (41.4) 748 (41.4) 154 (41.40) 2705 (41.4)
  south 880 (40.4) 724 (40.0) 156 (41.94) 2641 (40.4)
  West 178 (8.2) 151 (8.4) 27 (7.26) 535 (8.2)
comorbid illness, n (%)
  Hypertension 1179 (54.1)* 908 (50.2) 271 (72.9) 1838 (28.1)
  Diabetes 602 (27.6)* 481 (26.6) 121 (32.5) 654 (10.0)
  TiA 196 (9.0)* 83 (4.6) 113 (30.3) 62 (1.0)
  cOPD 189 (8.7)* 134 (7.4) 55 (14.8) 250 (3.8)
  cHF 138 (6.3)* 84 (4.7) 54 (14.5) 160 (2.5)
  Mi 54 (2.5)* 26 (1.4) 28 (7.5) 42 (0.6)
Notes: All comparisons are relative to the control cohort and are computed by t-test for continuous measures or χ2 test for dichotomous or ordinal measures. *P , 0.001. 
Abbreviations: cHF, congestive heart failure; cOPD, chronic obstructive pulmonary disease; Mi, myocardial infarction; TiA, transient ischemic attack.Vascular Health and Risk Management 2010:6 submit your manuscript | www.dovepress.com
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events versus 9 incident TIA events per 1000 patient-years). 
  Similarly, the rates of MI and fatal MI were higher among 
stroke patients compared with general-population controls 
(11 incident MIs versus 6 incident MIs per 1000 patient-
years; 2 fatal MIs versus ,1 fatal MI per 1000 patient-years); 
however, this did not reach statistical significance. Recurrent 
stroke patients had the highest risk of all-cause mortality 
(86 deaths per 1000 patient-years), followed by new stroke 
patients and controls (37 deaths and 4 deaths per 1000 patient-
years, respectively) (Table 2).
The average cost of index hospitalization was $15,634 (SD 
$27,536) for new stroke patients and $17,121 (SD $53,693) 
for recurrent stroke patients (Table 3). Among the 168 (2.6%) 
patients in the control cohort with a hospitalization on the 
index date, the average cost of hospitalization was $11,281 
(SD $29,052). Patients in the stroke cohort had significantly 
greater costs in the first year following the index event com-
pared with controls. Medical costs averaged $23,725 (SD 
$58,227) per stroke patient compared with an average of 
$5142 (SD $16,619) per control. Similarly, pharmacy costs 
averaged $2950 (SD $3549) per stroke patient compared with 
an average of $1388 ($2302) per control. Total combined 
costs were $26,675 (SD $58,605) per stroke patient per year. 
Recurrent stroke patients had 38% higher costs compared 
with new stroke patients, averaging $34,639 per patient in the 
first year following discharge from the index hospitalization 
compared with $25,036 per new stroke patient.
Adjusted analysis
After adjusting for covariates, results from the Cox pro-
portional hazards model suggested that stroke patients 
were 2.4 times more likely to be hospitalized in follow-up 
compared with control subjects (HR 2.4; 95% CI: 2.2–2.6) 
(Table 4). Older age was associated with a greater risk 
of hospitalization, with a 2% increase in hazard of being 
hospitalized for each additional year of age (P , 0.001). 
Patients who were male and who lived in the Northeast had 
a lower hazard of being hospitalized by 8% (95% CI: 0.8, 
1.0) and 13% (95% CI: 0.7, 1.0), respectively. In addition, 
patients with pre-index comorbid conditions had higher 
hazards of being hospitalized over the follow-up compared 
to patients without these conditions. Specifically, the haz-
ard of hospitalization was higher by 26% for hypertension 
(95% CI: 1.1, 1.4), 28% for diabetes (95% CI: 1.1, 1.4), and 
29% for TIA (95% CI: 1.1, 1.4). Patients with COPD faced 
even higher increases in the risk of hospitalization, with a 
57% increased hazard compared to patients without COPD 
(95% CI: 1.3, 1.8). CHF and MI also conferred additional 
risk of hospitalization by 79% and 50%, respectively (CHF 
95% CI: 1.5, 2.1; MI 95% CI: 1.1, 2.1). Cox proportional 
hazards model results indicated that occurrence of stroke 
following discharge was 21 times more likely among stroke 
patients compared with control subjects (95% CI: 16.1–27.3) 
(Table 5). No other covariates were significant predictors 
of subsequent stroke in this model. Being in the stroke 
cohort was predictive of death in follow-up after adjusting 
for covariate (Table 6); stroke patients were 1.8 times more 
likely to die in follow-up compared with control patients 
(95% CI: 1.3–2.5). Diagnosis of TIA in the pre-index period 
was the only other covariate that was statistically significant 
in the model; patients with pre-index TIA had a hazard of 
dying that was 2.3 times that of patients without prior TIA 
(95% CI: 1.3, 4.0).
Stroke patients had significantly higher costs compared 
with control patients in the year following the index event 
controlling for age, gender, region, and comorbid   conditions 
(Table 7). Total costs were 3.8 times higher among stroke 
patients compared with control patients, ranging from 
3.4 times to 4.3 times higher (P , 0.001). Compared to 
patients without these comorbid condition, hypertension, 
diabetes, COPD, and CHF, all were associated with higher 
costs in follow-up, with cost ratios ranging from 1.2 higher 
Table 2 Unadjusted rates of clinical events during follow-up period
Patients with an event (%) 
[rate per 1000 patient-years]
Total ischemic stroke  
cohort (N = 2180)
New stroke 
(N = 1808)
Recurrent stroke 
(N = 372)
Control cohort 
(N = 6540)
Hospitalization 752 (34.5) [307] 619 (34.2) [294] 133 (35.8) [382] 1387 (21.2) [100]
Any stroke 340 (15.6) [115] 272 (15.0) [107] 68 (18.3) [165] 73 (1.1) [5]
Fatal stroke 19 (0.9) [6] 15 (0.8) [5] 4 (1.1) [8] 3 (0.1) [0]
Hemorrhagic stroke 45 (2.1) [13] 33 (1.8) [12] 12 (3.2) [25] 14 (0.2) [1]
Fatal hemorrhagic stroke 5 (0.2) [1] 4 (0.2) [1] 1 (0.3) [2] 1 (0.0) [0]
TiA 483 (22.1) [186] 388 (21.5) [173] 95 (25.5) [266] 138 (10.0) [9]
Mi 38 (1.7) [11] 32 (1.8) [11] 6 (1.6) [12] 101 (1.5) [6]
Fatal Mi 7 (0.3) [2] 5 (0.3) [2] 2 (0.5) [4] 5 (0.1) [0]
All-cause mortality 151 (6.9) [44] 108 (6.0) [37] 43 (11.6) [86] 69 (1.1) [4]
Abbreviations: Mi, myocardial infarction; TiA, transient ischemic attack.Vascular Health and Risk Management 2010:6 submit your manuscript | www.dovepress.com
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for diabetes (95% CI: 1.1, 1.5) to 1.6 higher for CHF (95% 
CI: 1.2, 2.1). Increasing age was associated with a small 
(,1% per year of age) but statistically significant increase 
in cost (P , 0.001).
Discussion
The results of our study are consistent with those reporting 
significant adverse clinical and cost consequences of non-
cardioembolic ischemic stroke in other patient populations. 
Moreover, the study supports previous research showing that 
patients with recurrent stroke generally fare worse and cost 
more than patients experiencing first ischemic stroke, which 
may be related to the overall severity of the stroke for recur-
rent compared with first stroke. Severe strokes cost twice 
as much as mild strokes, despite similar diagnostic testing. 
In a population study of stroke costs within 30 days of an 
acute event, the average cost was $7200 for mild ischemic 
strokes and $12,400 for severe ischemic strokes (4 or 5 on 
the Rankin Disability Scale).15 Inpatient hospital cost for an 
acute stroke event accounts for 70% of first-year poststroke 
cost.16 The largest components of acute care cost are room 
Table 3 Cost of hospitalization for stroke and first year follow-up costs (per patient per year)
Mean ± SD Stroke cohort 
(N = 2180)
New stroke 
(N = 1808)
Recurrent stroke 
(N = 372)
Control cohort 
(N = 6540)
index hospitalization costs $15,888 ± $33,466* $15,634 ± $27,536 $17,121 ± $53,693 $11,281 ± $29,052a
1-year follow-up costs
Medical costs $23,725 ± $58,227* $22,099 ± $53,690 $31,625 ± $76,138 $5142 ± $16,619
Pharmacy costs $2950 ± $3549* $2937 ± $3577 $3014 ± $3416 $1388 ± $2302
combined medical and pharmacy $26,675 ± $58,605* $25,036 ± $54,052 $34,639 ± $76,586 $6530 ± $17,167
Notes: All comparisons are relative to the control cohort and are computed by t-test. aMean costs reported for 168 control subjects with a hospitalization on the index 
date. *P , 0.001.
Table 4 cox proportional hazards analysis of time to hospitalization
Cox proportional hazards model
Hazard 
ratio
SE P value 95% CI 
lower
95% CI 
upper
stroke 2.368 0.116 0.000 2.152 2.606
Age 1.023 0.002 0.000 1.019 1.027
Male 0.918 0.040 0.050 0.842 1.000
Midwest 1.037 0.050 0.453 0.944 1.138
Northeast 0.826 0.065 0.015 0.708 0.963
West 0.909 0.078 0.268 0.768 1.076
Hypertension 1.259 0.061 0.000 1.146 1.383
Diabetes 1.281 0.072 0.000 1.148 1.430
TiA 1.288 0.131 0.013 1.055 1.572
cOPD 1.568 0.122 0.000 1.347 1.826
cHF 1.753 0.155 0.000 1.475 2.085
Mi 1.495 0.251 0.017 1.076 2.078
Abbreviations:  CHF,  congestive  heart  failure;  CI,  confidence  interval;  COPD, 
chronic  obstructive  pulmonary  disease;  Mi,  myocardial  infarction;  sE,  standard 
error; TiA, transient ischemic attack.
Table 5 cox proportional hazards analysis of time to stroke
Cox proportional hazards model
Hazard 
ratio
SE P value 95% CI 
lower
95% CI 
upper
stroke 20.964 2.826 0.000 16.096 27.304
Age 1.031 0.004 0.000 1.023 1.039
Male 0.841 0.084 0.082 0.692 1.022
Midwest 1.023 0.112 0.833 0.825 1.269
Northeast 0.886 0.151 0.477 0.634 1.237
West 0.899 0.177 0.590 0.611 1.323
Hypertension 1.028 0.111 0.797 0.832 1.270
Diabetes 1.066 0.125 0.588 0.846 1.342
TiA 1.175 0.205 0.355 0.834 1.655
cOPD 1.255 0.205 0.163 0.912 1.728
cHF 1.355 0.258 0.111 0.933 1.968
Mi 1.334 0.420 0.361 0.719 2.474
Abbreviations:  CHF,  congestive  heart  failure;  CI,  confidence  interval;  COPD, 
chronic  obstructive  pulmonary  disease;  Mi,  myocardial  infarction;  sE,  standard 
error; TiA, transient ischemic attack.
charges (50%), medical management (21%), and diagnostic 
costs (19%).17 Comorbidities such as ischemic heart disease 
may also predict higher costs.18
In our managed care population, the recurrent stroke 
patients had poorer outcomes on all measures. Although the 
study designs differed, our findings were consistent with those 
of Samsa et al7 which pertained exclusively to a Medicare 
patient population. The interpretation of the results comparing 
recurrent and new stroke requires some caution. Our recurrent 
stroke subgroup represented approximately 17% of all strokes 
based on a 12-month pre-index evaluation. This estimate is 
below the national rate of 29% reported by the American Heart 
Association.6 The difference between the estimates likely stems 
from the limited pre-index evaluation. Prior strokes may have 
occurred in a larger population than were identified in only the 
12 months evaluated. In addition, the impact of inappropriately 
designating some patients as new stroke patients rather than 
recurrent stroke patients may falsely inflate adverse outcomes 
and costs among new stroke patients. However, despite this 
risk, the differentials between new and recurrent stroke patients 
in clinical outcomes and costs were substantial.Vascular Health and Risk Management 2010:6 submit your manuscript | www.dovepress.com
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As in other studies, clinical outcomes such as hospi-
talization, additional stroke, and death were substantially 
higher among stroke patients compared with controls and 
among recurrent stroke patients compared with new stroke 
patients. Although our measurement period was different 
from that used by Samsa et al7 and by Vickery et al,19 trends 
in reported outcomes were similar. TIA and stroke were the 
most common clinical events occurring in the follow-up 
period. However, compared with Vickery et al,19 our rates 
of subsequent stroke were much lower.
This study confirms previous reports that patients with 
ischemic stroke and TIA are more at risk for recurrent cere-
brovascular events compared with cardiac events.20–22 In a 
retrospective study of patients with ICD codes for ischemic 
stroke/TIA, Brown et al21 reported that cardiac events at 
2 years had occurred in 7.7% of patients. Acute MI was the 
most common cardiac event reported. We found similar rates 
of MI (1.7%) compared with results reported by Vickery 
et al (1.5%).19
Similar to our study, Samsa et al7 found that in a Medicare 
population, recurrent stroke patients experienced a greater 
cost burden in 1 year following the index event compared 
with new stroke patients. All stroke patients had substantially 
higher costs than controls. Samsa et al7 reported that the cost 
burden for new and recurrent stroke the first year, including 
index hospitalization, was approximately $29,000 and $32,000, 
respectively. At the time of the Samsa7 study, Medicare did not 
cover outpatient pharmacy costs, which represented ∼11% of 
total cost in our study. In addition, other technological changes 
that have increased the cost of health care in general are likely 
contributing to the overall higher burden of illness observed in 
our study. Interestingly, according to the American Heart Asso-
ciation, 36% of direct health care costs are allocated toward 
nursing home care. Because the commercial health plan covers 
only limited short-term nursing home care, our study probably 
underestimates the overall true burden of stroke.23
In addition to the limitations described above in the 
interpretation of our data, additional limitations may impact 
the results reported here. First, as with all studies relying on 
retrospective administrative claims data, there are limits to the 
degree to which claims data can accurately capture an indi-
vidual’s medical history. Also, although comorbid conditions 
were considered controls in the modeling, the underlying health 
status of the stroke cohort may have been considerably worse 
than the control patients, resulting in the inappropriate attri-
bution of rate and cost differentials to the presence of stroke. 
However, because stroke may occur in otherwise healthy adults 
and the major comorbidities contributing to excess costs were 
accounted for in the analysis, including hypertension and 
diabetes, we believe that the substantial burden of stroke is 
accurately reflected in this analysis. It is possible that the study 
underestimated the cost burden of stroke; the stroke popula-
tion had a shorter length of follow-up than the control cohort, 
and it is not known how large the health care costs were for 
patients who disenrolled from the health plan and switched 
to another insurer or became uninsured. In addition, since 
the measure of mortality was based upon hospital discharge 
status in the claims, additional deaths may have occurred 
outside the inpatient setting that would not have been identi-
fied for the study. Estimates of re-hospitalization were based 
upon the identification of claims for inpatient sites of service 
Table 6 cox proportional hazards analysis of time to death
Outcome Cox proportional hazards model
Hazard 
ratio
SE P value 95% CI 
lower
95% CI 
upper
stroke 1.808 0.310 0.001 1.291 2.531
Age 0.990 0.006 0.099 0.979 1.002
Male 1.102 0.166 0.520 0.820 1.479
Midwest 0.965 0.156 0.825 0.703 1.324
Northeast 1.230 0.316 0.420 0.744 2.034
West 1.540 0.458 0.147 0.859 2.759
Hypertension 0.947 0.145 0.719 0.702 1.277
Diabetes 0.883 0.154 0.474 0.627 1.242
TiA 2.290 0.643 0.003 1.321 3.969
cOPD 1.392 0.278 0.098 0.941 2.060
cHF 1.082 0.220 0.697 0.727 1.611
Mi 1.006 0.322 0.984 0.537 1.885
Abbreviations:  CHF,  congestive  heart  failure;  CI,  confidence  interval;  COPD, 
chronic  obstructive  pulmonary  disease;  Mi,  myocardial  infarction;  sE,  standard 
error; TiA, transient ischemic attack.
Table  7  generalized  linear  modeling  of  per-patient-per-year 
total costs
Generalized linear model
Cost ratio 
(ExpB)
SE P value 95% CI 
lower
95% CI 
upper
stroke 3.821 0.242 0.000 3.375 4.325
Age 1.008 0.002 0.000 1.004 1.013
Male 1.011 0.054 0.838 0.911 1.122
Midwest 0.939 0.054 0.276 0.838 1.052
Northeast 0.945 0.087 0.539 0.788 1.133
West 1.006 0.101 0.951 0.827 1.224
Hypertension 1.348 0.081 0.000 1.198 1.516
Diabetes 1.247 0.100 0.006 1.065 1.460
TiA 1.064 0.167 0.692 0.782 1.447
cOPD 1.445 0.177 0.003 1.137 1.836
cHF 1.560 0.235 0.003 1.162 2.094
Mi 1.327 0.338 0.266 0.806 2.186
Abbreviations:  CHF,  congestive  heart  failure;  CI,  confidence  interval;  COPD, 
chronic  obstructive  pulmonary  disease;  ExpB,  exponentiated  coefficients;  MI, 
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(excluding nursing homes or skilled nursing facilities), but it 
is possible that some acute rehabilitation hospitals may have 
been included in this measure.
Results of this analysis are primarily applicable to 
managed care settings. The plans used for analysis, however, 
are discounted fee-for-service plans rather than capitated 
or gatekeeper models. They include a wide geographic 
distribution across the United States and thus provide the 
capability for generalization to managed care populations on 
a national level. However, these results cannot be extrapolated 
to represent the association between stroke and clinical and 
cost outcomes in a solely Medicare patient population or 
among the uninsured. As discussed previously, the inability 
to identify costs after patients disenrolled from the health plan 
also suggests that this finding may somewhat under-represent 
costs for ischemic stroke patients; health care systems in 
which the payers are responsible for patients’ costs throughout 
their life span may face a higher cost burden. In addition, 
these results may not be generalizable to cardioembolic 
stroke; this analysis was limited to patients without AF 
or mitral valve abnormalities, as the intense management 
required for AF or valve abnormalities may result in differ-
ent clinical outcomes, utilization patterns, and costs for this 
subset of patients than those experienced by patients with 
noncardioembolic stroke.
The findings of this study highlight the need for an urgent 
approach to diagnosis and treatment in order to prevent 
noncardioembolic ischemic stroke and stoke recurrence. 
Because treatment of patients with acute ischemic stroke 
is challenging and presents its own risks to the patient,24 
prevention is a crucial strategy. Evidence-based and 
consensus-based guidelines advocate the use of antiplatelet 
agents, anticoagulants (where appropriate), and antihyperten-
sive medications for the prevention of secondary stroke.25
In conclusion, noncardioembolic ischemic stroke patients 
represent a significant burden on the managed care system, 
and despite its relatively lower prevalence rate, recurrent 
stroke disproportionately contributes to higher costs and 
negative clinical outcomes.
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